Agile Licensing: drug and device oversight

Summary#

These are the final Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Agile Licensing) (registered as SOR/2024-238). They change how Health Canada oversees drugs and some medical devices across their whole lifecycle, adding new tools for pre‑ and post‑market checks and fast access in emergencies. Many parts took effect when the notice was published (Canada Gazette, Part II) on December 18, 2024, while several key rules start on July 1, 2025, January 1, 2026 and April 1, 2027.

What it does#

Major changes in plain language:

• Lets the Minister impose or change enforceable terms and conditions (T&Cs) on the drug identification number (DIN) for any drug at the time of authorization or later.

  • Same power is broadened for Class II, III and IV medical device licences.
  • T&Cs can require studies, monitoring or other actions to manage risks or uncertainties.

• Requires risk management plans (RMPs) in certain situations for human drugs.

  • RMPs must describe risks, how the manufacturer will manage them, and include an English and French summary.
  • The Minister can ask for new or updated RMPs after a product is on the market if risks or uncertainties change.

• Expands COVID‑era flexibilities to other “public health emergency drugs.”

  • Introduces a “List of Conditions that Threaten Public Health” (kept on the government website) and applies rolling review, pre‑positioning and other flexibilities to drugs tied to those conditions.
  • Rolling review lets Health Canada begin assessing some parts of an application before every piece of data is submitted.

• Modernizes rules for biologic drugs (Schedule D) by replacing old product‑by‑product rules with broader, outcome‑based requirements.

  • Clarifies lot release, contamination prevention, labelling, and storage (including during transportation).

• Tightens and clarifies quality expectations across all drugs: fabricated, labelled, tested and stored (including during transport) in a way that assures quality.

• Lets Health Canada consider information from other sources when reviewing a submission (for example, on‑site inspection results or trusted foreign regulator reports).

• Requires clinical trial data broken down by subgroups when that disaggregated data has already been given to the US FDA or EMA.

• Eases some labeling and standards rules: manufacturers using their own standards for many new drugs no longer must meet the single most stringent limit across all pharmacopoeias, and in many cases labels no longer must state which standard was used (some exceptions, e.g. radiopharmaceuticals, remain).

Key timing (selected):

• In force on publication (December 18, 2024): public health emergency drug rules, rolling reviews and pre‑positioning, quality‑during‑manufacturing language, ability to use outside information, disaggregated data and standards updates.
• July 1, 2025: new biologics (Schedule D) rules.
• January 1, 2026: expanded T&Cs for Class II–IV medical devices.
• April 1, 2027: T&Cs for all drugs and RMP requirements come fully into force.

Who's affected#

• Health Canada will use the new authorities to review and monitor products.
• Drug manufacturers and applicants (human and veterinary), including makers of biologics and radiopharmaceuticals.
• Medical device manufacturers with Class II, III or IV licences.
• Establishment licence holders, importers, distributors and fabricators involved in storage, transport, packaging and testing.
• Health systems, hospitals and health professionals who may see changes in product labelling, safety information and post‑market data.
• Small businesses in the sector — the regulatory analysis estimated about 225 small businesses could be affected.
• The public: patients and caregivers could see earlier access to emergency drugs, different risk information, or new post‑market safety measures.

Costs and savings estimated by the government (10‑year view):

• Estimated incremental cost to industry: $183 million (present value).
• Estimated cost to government: $7 million (present value).
• Total estimated cost: $190 million (present value).
• Estimated savings from removing some standards labelling/monitoring rules: $62 million (present value).
• Estimated net cost: $128 million (present value).

Why it matters#

• More tools to manage safety after a product is on the market. T&Cs and RMPs let Health Canada require ongoing studies, reporting or other steps instead of relying only on pre‑market data. That can keep useful products available while reducing risk.
• Faster access in emergencies. The rolling review and pre‑positioning rules, now available beyond COVID‑19, are meant to speed availability of drugs during public health crises.
• Better alignment with other regulators. The changes bring Canada closer to practices used by regulators such as the US FDA and EMA, especially on RMPs and reliance on foreign information.
• Manufacturers face new obligations and costs. Companies should expect to prepare RMPs, possibly comply with T&Cs, and submit certain disaggregated trial data when available. This can mean real additional work and expense.
• For patients and clinicians, the changes aim to improve safety monitoring and transparency (bilingual RMP summaries, clearer quality expectations), though some impacts will only appear as Health Canada implements procedures and guidance.

If anything above is unclear in the official text, the Canada Gazette posting gives the full regulatory language and the Regulatory Impact Analysis Statement with more detail.